Response after single treatment with canakinumab predicts which patients will benefit most
A new analysis seeks to answer the question of which patients are likely to gain the greatest cardiovascular benefit when treated with the anti-inflammatory agent canakinumab. At the 2017 American Heart Association Scientific ...
Nov 13, 2017